• Users Online: 149
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most popular articles (Since November 26, 2015)

 
 
  Archives   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
ALTERNATIVE MEDICINE
Homeopathic management of warts
Piyush Mahendra Oza
January-June 2016, 2(1):45-47
DOI:10.4103/2455-3972.184085  
Warts are classified under one sided diseases as external local maladies. They often have individualistic and immunological basis as also familial tendencies. Warts are included under miasm sycosis. Although warts are local diseases, they are treated with internal remedy which is based on comprehensive understanding of the patient. This includes local symptoms, i.e. morphology and location of lesion, mental makeup of the person, and physical characteristics. This is what is called totality of symptoms. A constitutional remedy thus selected eradicates the complaint locally as well as internally, thereby providing long lasting relief from complaints. Common remedies include Calcarea carbonica, Causticum, Dulcamara, Natrum muriaticum, Nitric acidum, and Thuja occidentalis. Homeopathic concept and homeopathic treatment of warts has been described.
  35,907 312 -
MANAGING A SIDE EFFECT
Acute methotrexate toxicity
Bhushan Madke, Adarsh Lata Singh
July-December 2015, 1(1):46-49
DOI:10.4103/WKMP-0110.170764  
  16,958 1,308 -
EDITORIAL
Tranexamic acid in melasma: Why and how?
Shuken Dashore, Katyain Mishra
July-December 2017, 3(2):61-63
DOI:10.4103/ijdd.ijdd_37_17  
  17,668 580 -
ALTERNATIVE MEDICINE
Management of vitiligo: An ayurvedic perspective
Anuradha Khandekar, Jyoti H Jadhav, Sunder Singh K Danga
July-December 2015, 1(1):41-43
DOI:10.4103/WKMP-0110.170752  
Shwitra or Shwet-Kushtha can be co-related with skin disease "vitiligo" in biomedicine. According to Ayurveda, the skin is one of the essential sense organs. Vata and bhrajaka pitta reside in the skin (called twak in Sanskrit). As the skin covers the whole body, bhrajaka pitta should be maintained in a proper state, and it needs continuous care. An imbalance in Vata and bhrajaka pitta may cause skin diseases. The first step (Step 1) in Ayurvedic management of vitiligo is purification therapies (shodhana karma) using herbal decoction of Psoralea corylifolia (bakuchi kwatha) and Euphorbia neriifolia (snuhi) aimed to induce multiple bouts of purgation. In the next step (Step 2), oil massage using oil selected on the basis of patient examination (rogi pariksa) and disease (roga). Step 3 is the exposure of lesions to the sun rays as long as the patient can tolerate (Soorya pada santhapam in Ayurveda). Herbomineral preparations include topical application of herbal Lepa, powders made up of medicinal plants (Curna), herbalized ghee preparations similar to paste (Ghrita, semi-solid preparations taken orally, by licking (Avaleha), herbalized oil preparations (Thaila), fermented solutions (Asava-Arista), and tablets (Vati/Gutika). Various minerals and metallic salts (Rasousadha) are also used. Bakuchi oil is Ayurvedic medicinal oil prepared from the dried fruits of P. corylifolia, and sesame oil is a popular therapy for vitiligo in Ayurveda that contain psoralen to stimulate melanocytes when exposed to ultraviolet light exposure. Details of above-mentioned therapy are discussed. Scientific rationale behind the use of these medications needs to be further explored with modern methods and research.
  17,574 521 -
REVIEW ARTICLE
Apremilast: A dermatologic perspective
Aditya Kumar Bubna
July-December 2016, 2(2):75-82
DOI:10.4103/2455-3972.196166  
Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administration in the management of psoriatic arthropathy (PsA). As biologic therapy is associated with significant amounts of adverse effects, newer treatment options with an efficacious outcome, sans the toxicity, is something all clinicians would implement readily in their therapeutic regimens. Apremilast is one such drug which has shown promise in the management of psoriasis, PsA, and a few other dermatologic disorders. This review will throw light on the dermatologic perspective regarding apremilast.
  7,039 1,018 -
REVIEW ARTICLES
Second-generation antihistamines
Pranjal Anil Mittal, Kiran V Godse, Sharmila P Patil
January-June 2016, 2(1):3-12
DOI:10.4103/2455-3972.184094  
Clinical trials have proved the efficacy of antihistamines in the treatment of chronic idiopathic urticarial (CIU). Second-generation antihistamines are recommended as first-line therapy for CIU. This article reviews the newer second-generation antihistamines in light of recent advances in the understanding of their pharmacology, efficacy, and safety profile. A Google scholar search for second-generation antihistamines was done using the words “second generation H1antihistamines,” “bilastine,” “ebastine,” “olopatadine,” “rupatadine,” “levocetirizine,” “fexofenadine,” “desloratadine,” “histamine,” “allergy,” and “urticaria.” All the articles were retrieved and classified into review articles, studies, double-blinded trials, and case reports. The final data were then analyzed and presented in a narrative fashion.
  6,810 935 -
LETTERS TO EDITOR
Sebaceous hyperplasia: Treatment with combination of oral isotretinoin and salicylic acid chemical peeling
Sushil Kakkar, Prafulla K Sharma
July-December 2016, 2(2):106-107
DOI:10.4103/2455-3972.196174  
  6,160 90 -
ORIGINAL ARTICLES
Topical 2% mupirocin versus 2% fusidic acid versus 1% nadifloxacin cream in the treatment of superficial bacterial infections of the skin
Resham J Vasani, Sudhir V Medhekar
July-December 2015, 1(1):16-18
DOI:10.4103/WKMP-0110.170744  
Introduction: Topical mupirocin, fusidic acid, and nadifloxacin are used in the treatment of superficial bacterial infections. This study was undertaken to assess the efficacy and safety of these three topical antibiotics in the treatment of superficial bacterial infection of the skin. Aims: To compare the efficacy and safety profile of 2% mupirocin versus 2% fusidic acid versus 1% nadifloxacin cream in the treatment of superficial bacterial infections. Materials and Methods: A randomized study in treatment-naive cases of uncomplicated bacterial skin infections attending the out-patient Department of Dermatology was done. A total of 90 patients of bacterial infections of the skin were included, which were randomly allocated to three different study groups. After diagnosis was confirmed clinically, grading of the lesions was done with regard to parameters such as erythema, edema, vesiculation, pustulation, crusting, and scaling. Score was applied to each parameter as 0-absent, 1-mild, 2-moderate, and 3-severe. Gram staining was performed. The lesions were graded on subsequent visits on day 4, day 18, and day 14. The results were subjected to analysis of variance test, followed by the Dunnett's test. Results: Fusidic acid cream showed faster reduction of the scores at the end of the first visit. The differences noted in the efficacy of the three drugs were not statistically significant. No significant side effects were observed. Conclusion: This study documents the equality in the comparative safety and efficacy of mupirocin, fusidic acid, and nadifloxacin in the treatment of uncomplicated superficial bacterial infections at our center.
  5,751 409 -
REVIEW ARTICLES
Itraconazole: What clinicians should know?
Piet De Doncker, Sushil Pande, Ute Richarz, Nishant Garodia
January-June 2017, 3(1):4-10
DOI:10.4103/ijdd.ijdd_20_17  
Our purpose in assembling this paper is 2-fold. First, we hope to review in-depth the properties on itraconazole pellet-capsules and what clinicians should know when considering oral itraconazole and discuss the potential value of treating superficial dermatophyte infections with oral antifungal therapy. Second, we hope to address some of the concerns of the recent epidemic of chronic recalcitrant widespread dermatophytosis in India, with emphasis on better treatment but also considering some of the necessary prophylaxis hygiene measures. An in-depth review of itraconazole (as pellet-capsules), a triazole antifungal will be presented with focus on the pharmacokinetic properties which lead to the development of the 1-week pulse dosing for skin and nail infections. Finally, recommendations for best usage of itraconazole pellet-capsules for management of dermatophytosis will be summarized in this paper.
  5,016 835 2
REVIEW ARTICLE
Bepotastine besilate: A novel anti-histamine
Kiran Godse, Neeti Kumari
July-December 2017, 3(2):64-68
DOI:10.4103/ijdd.ijdd_22_17  
Oral bepotastine is a nonsedative second-generation antihistamine with an action on other inflammatory mediators. It also acts as a mast cell stabilizer and leukotrienes inhibitor. Its distribution in the brain is very limited. We explored the currently available literature on bepotastine besilate to assess the pharmacodynamics and pharmacokinetics of the drug and its role in pruritus and urticaria. Bepotastine is generally well tolerated in the elderly population and pediatric patients. Safety of bepotastine in children >2 years of age, pregnant and lactating females is not known. Bepotastine has got very minimal side effect. In comparison to many other second-generation antihistamines, it has got the quicker onset of action, and it maintains its efficacy over the time. It is a promising agent in the treatment of urticaria, allergic rhinitis, and pruritus associated with different skin disorders.
  5,117 467 -
TABLE
Maculopapular drug eruption versus maculopapular viral exanthem
Bhavana R Doshi, BS Manjunathswamy
January-June 2017, 3(1):45-47
DOI:10.4103/ijdd.ijdd_19_17  
  4,842 394 -
ORIGINAL ARTICLES
Effect of measles mumps rubella vaccine in treatment of common warts
Anuja Dhope, Bhushan Madke, Adarsh Lata Singh
January-June 2017, 3(1):14-19
DOI:10.4103/ijdd.ijdd_1_17  
Background: There are many destructive and immunotherapeutic options available for the treatment of common warts, but no treatment is 100% effective and usually cause pain and scarring. Recently, intralesional immunotherapy with skin test antigens and vaccines has been shown to be effective in the management of warts. We evaluated the efficacy of Measles Mumps Rubella (MMR) vaccine injection in the treatment of cutaneous warts. Aim: To study the efficacy of intralesional MMR vaccine in the treatment of common warts. Materials and Methods: A case–control study was conducted in AVBR Hospital, Sawangi (Meghe), Wardha, in 2015–2016. Forty clinically diagnosed cases of cutaneous common wart were selected in the study and were put randomly into two groups (20 in each group). Group 1: included twenty patients subjected to intralesional injection of 0.5 ml MMR vaccine. Group 2: included twenty patients as a control group and subjected to intralesional injection of 0.5 ml saline. These injections were repeated every 3 weeks intervals for maximum three injections. Follow-up of patients was done every 6 months for clinical assessment of results and to study recurrence. Results: A significant difference was found between the therapeutic responses of common warts to MMR. Vaccine and normal saline (control) group. At the end of 9 weeks (third visit), about 65% patients treated with MMR vaccine showed complete clearance compared with 5% of the control group. Grade 3 response was 20% versus 10% respectively; whereas Grade 2 response was observed in 10% versus 25%, respectively, and as regards no response, it was 5% versus 60% in MMR vaccine and control group, respectively. Conclusion: We found that the treatment of common warts by MMR vaccine is effective, with good cure rates, and excellent safety profile.
  4,898 312 -
Tuberculin purified protein derivative immunotherapy in the treatment of viral warts
Ajay Nimbalkar, Sushil Pande, Ramesh Sharma, Milind Borkar
January-June 2016, 2(1):19-23
DOI:10.4103/2455-3972.184103  
Introduction: Viral warts are caused by human papillomavirus. Although various treatment modalities are available, many of them result in the partial clearance of warts or recurrence. Immunotherapy has been tried in the recent times with variable success rates. We undertook a study to evaluate the safety and efficacy of immunotherapy using tuberculin purified protein derivative (PPD) for the treatment of viral warts. Materials and Methods: A total of 45 patients were included in the study. Each patient was injected with 10 TU of tuberculin PPD (0.1 ml) intralesionally in the largest wart at 2 weekly interval. A total of maximum six treatment sessions were conducted. Resolution of viral warts was considered as the clinical end point of the study. The clinical assessment was done by photographic measurements at baseline, before each treatment session, and 3 weeks after the completion of treatment. Results: A total of 62.2% patients (28 out of 45) showed complete clearance at injected and distant warts, eight patients (17.8%) showed partial clearance, and nine patients (20%) showed no improvement. No significant side effects were observed except for localized hair loss around injected viral wart over the scalp. Conclusion: Tuberculin PPD immunotherapy was found to be a safe and effective treatment modality for the treatment of viral warts.
  4,865 321 -
TABLE
Drug-induced fever versus infection-induced fever
Sagar Jugtawat, Bhagyashri Daulatabadkar, Sushil Pande
July-December 2016, 2(2):115-116
DOI:10.4103/2455-3972.196224  
  4,694 335 -
CASE REPORTS
Acitretin: A good treatment option for hypertrophic lichen planus
Rameshwar M Gutte
January-June 2016, 2(1):28-30
DOI:10.4103/2455-3972.184096  
Lichen planus (LP) is a chronic inflammatory dermatosis of unknown etiology characterized by pruritic violaceous papules. Here, we share our experience of a long standing case of disseminated hypertrophic LP treated with oral acitretin. A 48-year-old married male, presented with multiple highly itchy dark raised lesions over bilateral legs since 15 years. There was no history of any preceding trauma, any recent drug intake before eruption, dental metal fillings, hepatitis, or any other infection. Patient was treated with oral antihistamines and topical moisturizers and topical steroid and salicylic acid combination ointments in the past with only temporary relief. Clinical examination revealed multiple hyperpigmented keratotic papulonodular lesions over bilateral legs and few on feet. Mucous membranes were normal. He was started on acitretin 25 mg twice daily along with oral hydroxyzine 25 mg and topical moisturizer and clobetasol and 6% salicylic acid ointment. After 2 weeks, patient noted up to 30–40% improvement in lesions and some became flat. Furthermore, itching was reduced. His lipid and liver profile showed no abnormality. Acitretin 25 mg bid and antihistamines were continued along with moisturizer for another 2 weeks. Since patient tolerated acitretin well without any major side effects,except for mucosal dryness and slight hair loss, it was continued for another 1 month. At the end of 2 months, there was almost 90% improvement in most of the lesions. Acitretin was stopped after 4 months. There was no recurrence reported up to 6 months posttreatment. Our case of HLP showed a good response to acitretin and it can be considered one of the treatment options for such severe, highly itchy cases of LP affecting quality of life.
  4,718 161 -
REVIEW ARTICLES
Role of clofazimine in management of reactions in leprosy: A brief overview
VV Pai
July-December 2015, 1(1):12-15
DOI:10.4103/WKMP-0110.170761  
Clofazimine is a synthetic dye that has been used in the treatment of leprosy since many years. Its role in the treatment of lepra reactions was subsequently recognized. When the dose of 300 mg/day is used, it doubles the serum concentration of the drug and supposedly exerts potent anti-neutrophilic effect and inhibits of prostaglandins. Our personal experience with high dosages of clofazimine in type II lepra reactions and review of the literature suggests that clofazimine has been extremely useful in providing good and satisfactory results in leprosy patients suffering from these embarrassing conditions. The anti-inflammatory effect of clofazimine is greatly useful in managing recurrent and chronic type II reactions with its steroid-sparing effect and providing an alternate and in expensive option.
  4,161 355 -
EDITORIAL
Steroid containing fixed drug combinations banned by government of India: A big step towards dermatologic drug safety
Sushil Pande
January-June 2016, 2(1):1-2
DOI:10.4103/2455-3972.184102  
  4,209 251 2
REVIEW ARTICLE
Bilastine: A novel antihistamine
Jeet Gandhi, Kiran Godse, Gauri Godse
January-June 2018, 4(1):3-6
DOI:10.4103/ijdd.ijdd_12_18  
Bilastine is a new second generation H1-antihistamine approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU) in patients older than 12 years of age. AR and urticaria are very common clinical conditions that represent one of the most frequent reasons for a patient to visit their general practitioner or allergist or dermatologist. Bilastine, with its efficacy and safety profile epitomizes the evolution of research on antihistamines.
  3,795 375 -
EDITORIAL
Clinical failure of antifungal therapy of dermatophytoses: Recurrence, resistance, and remedy
Ragunatha Shivanna, Arun C Inamadar
January-June 2017, 3(1):1-3
DOI:10.4103/ijdd.ijdd_13_17  
  3,594 570 -
CASE REPORTS
An alternative hepatosafe treatment in leprosy
Anuradha Ashok Bhide, Usha N Khemani, Ratnakar R Kamath, Varsha Vaidyanathan, Abhishek P Ponathil, Mahendra M Kura
January-June 2016, 2(1):33-36
DOI:10.4103/2455-3972.184086  
Leprosy complicated by hepatitis is one condition wherein the usual multidrug therapy cannot be used and alternate regimens are required. The World Health Organization and the Indian Association of Leprologists have recommended an alternative combination therapy of clarithromycin, ofloxacin, and clofazimine to be prescribed in such cases. However, in some cases, this combination therapy may fail to control or worsen the hepatitis. One such case of leprosy, complicated by hepatitis, who did not tolerate the recommended hepatosafe regimen was successfully treated with monthly rifampicin, ofloxacin, and minocycline, and is hence reported.
  3,751 277 -
Intralesional tranexamic acid: Safe and effective way of treatment for melasma
Vani Veggalam, Nataraj Perumalla
July-December 2017, 3(2):81-83
DOI:10.4103/ijdd.ijdd_24_17  
Many studies suggested the use of tranexamic acid (TA) as a treatment modality for melasma, however, there are many limitations in the use of oral and intravenous dosage forms of TA because of adverse effects and contraindications resulted by its thrombolytic property. Topical application of TA is not effective because of its poor penetration through epidermis. Intradermal injections into the localized lesions of melasma regions or intralesional administration of TA were reported to be effective way of treatment for melasma with minimum risk of adverse effects. We report a case of a 40-year-old woman, who was treated with a minimum effective dilution of intradermal TA at localized hyperpigmented regions. The results were noted and analyzed with photographs taken during the treatment and by considering the patient satisfaction scores. The patient showed good improvement at the end of 4 weeks.
  3,446 219 -
En coup de sabre treated with platelet-rich plasma
Vasudha Abhijeet Belgaumkar, Nitika S Deshmukh, Bhavana Ravindra Doshi, Chandrakant B Mhaske
July-December 2015, 1(1):27-29
DOI:10.4103/WKMP-0110.170747  
Contour defects such as linear morphea are difficult to treat and can be a cause for great cosmetic and sociopsychological morbidity. The pivotal discovery of platelet-derived growth factors in promoting wound healing, angiogenesis, and tissue remodeling has paved the way for various uses of platelet-rich plasma (PRP). We report a novel indication for this promising therapeutic modality with satisfactory results. A 24-year-old female presented with nonprogressive linear hyperpigmented atrophic lesion over the left supraorbital region and scalp of 15 years duration was diagnosed as linear morphea. She had taken immunosuppressants over the last 3 years with minimal improvement. PRP was obtained with a platelet count up to 2.5 times the baseline count. Calcium chloride (1:9) was added as an activator. About 3 ml of PRP was injected into the linear contour defect every week for a total duration of 12 weeks. The results were corroborated quantitatively by a repeat high frequency focal ultrasound which showed focal minimal irregularity over frontoparietal region of scalp corresponding to bony lesion measuring 0.5 cm × 1.8 cm (original defect of 1.4 cm × 1.8 cm). A remarkable reduction in hyperpigmentation of overlying skin was noted which further enhanced the cosmetic outcome. The effect was sustained until the end of follow-up period of 6 months after the last PRP sitting. No secondary changes or side effects were noted during the entire course of treatment. PRP therapy is safe and effective in the treatment of linear morphea over face and scalp as demonstrated in this case.
  3,276 138 -
LETTERS TO EDITOR
Azathioprine-induced alopecia as an early clinical marker of its myelotoxicity
Anil B Bhokare
January-June 2017, 3(1):40-41
DOI:10.4103/ijdd.ijdd_4_17  
  3,196 71 -
WHAT’S IN NEWS
Recent drug approvals in dermatology

July-December 2015, 1(1):57-58
DOI:10.4103/WKMP-0110.170766  
  2,894 219 -
ORIGINAL ARTICLES
Role of folic acid supplementation in reducing side effects of oral methotrexate in patients of psoriasis: A study
Tulika Rai, Satyendra Kumar Singh
July-December 2016, 2(2):83-86
DOI:10.4103/2455-3972.196167  
Background: Methotrexate (MTX) has been used for the treatment of severe psoriasis for more than 50 years. MTX use can be associated with many side effects, and folic acid is supplemented to reduce these side effects. MTX can be given orally or parenterally. Materials and Methods: In this study, a total of 81 patients of severe psoriasis were given 15 mg/week of MTX orally, and side effects were noted at each visit. Results: A total of 36 patients developed side effects, of which ten patients were discontinued due to the development of serious side effects. Remaining 26 patients developing nonserious side effects were given folic acid 5mg/day on non-MTX days and continued with 15 mg/week of MTX therapy. They were further evaluated for any improvement in side effects. Folic acid supplementation was associated with improvement in gastrointestinal and mucosal side effects in 17 out of 26 patients. Conclusion: Therapeutic effects were not compromised in all these patients after initiation of folic acid therapy. We recommend the supplementation of folic acid 5 mg/day in all patients of psoriasis who are receiving 15 mg/week of MTX therapy.
  2,851 189 -